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2  | MATERIAL S AND METHODS

















One	 centre	 starts	 fluconazole	 when	 surveillance	 cultures	 grow	
Candida.	 If	 surveillance	 cultures	 show	 Candida	 species	 resistant	
to	fluconazole,	some	centres	switch	to	amphotericin	B	suspension	
and	 one	 centre	 adds	 amphotericin	 B	 suspension	 to	 fluconazole.	
Finally,	one	centre	 stops	 fluconazole	and	no	other	prophylaxis	 is	
initiated.
3.1.2 | Mould- active prophylaxis









and	 consisted	of	 fluconazole	 and/or	 amphotericin	B	 suspension.	Mould-	active	prophylaxis	was	







sis	 and	 treatment	was	 apparent	 in	 the	Netherlands.	 Facing	 triazole-	resistance,	 consensus	was	
reached	on	the	implementation	of	a	uniform	diagnostic	approach	in	all	8	centres.
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Different	 Aspergillus	 susceptibility	 testing	 methods	 are	 used:	
VIPcheck™	 or	 Etest	 followed	 by	 confirmation	 with	 testing	 ac-
cording	to	the	European	Committee	on	Antibiotic	Susceptibility	
Testing	 (EUCAST)	method	when	 resistance	 is	 suspected	based	
on	 the	 screening	 assay	 (Table	3).	 The	 EUCAST	 method	 is	 op-
erational	 in	 the	 mycology	 reference	 laboratory	 (RefLab).	
Resistance	 screening	 is	 done	 in	 all	 but	 one	 centre	 with	 a	 4-	
well	plate	 (VIPcheck™)	 in	which	three	of	the	four	wells	contain	
agar	 supplemented	 with	 an	 azole	 (voriconazole,	 itraconazole	
and	 posaconazole)	 and	 the	 fourth	 functions	 as	 a	 growth	 con-
trol.	The	other	centre	uses	the	Etest	(bioMérieux)	for	resistance	
TABLE  1 Prophylactic	strategies	used	against	Candida	and	Aspergillus























































4  |     SCHAUWVLIEGHE Et AL.
screening.	 Simultaneous	 to	 the	 screening	 test,	 4	 centres	 send	
the	Aspergillus	strain	directly	to	the	RefLab	for	MIC	testing.	PCR	
testing	 for	 the	 presence	of	 TR34	 and	TR46	 directly	 on	 cultured	
A. fumigatus	colonies	is	performed	on-	site	in	4	centres	to	speed	





Suspected invasive fungal infection:
All	centres	use	voriconazole	as	the	initial	treatment	for	patients	in	a	
respiratory	stable	condition	suspected	of	having	an	IFD	while	wait-
ing	 for	 the	 microbiological	 tests	 (Table	4).	 One	 centre	 frequently	




and	 therefore,	 the	 detection	 of	 azole-resistance	 becomes	 more	
likely.	If	BAL	is	not	feasible,	this	centre	gives	L-	AmB	as	antifungal.
Proven or probable IA
Voriconazole	 is	 the	 treatment	 of	 choice	 for	 all	 centres	 when	 a	
BAL-	GM	assay	is	positive	in	a	respiratory	stable	patient	and	the	le-
sions	on	chest	CT	are	not	widespread,	fungal	culture	remains	neg-





Proven or probable IA and documented voriconazole 
resistance
If	voriconazole	resistance	 is	demonstrated	with	one	of	the	pheno-















characterisation.	101	 isolates	 (12.9%)	were	 triazole-	resistant,	which	
TABLE  3 Diagnostic	tests	done	on	BAL	fluid	samples














































4.1 | Prophylaxis directed at Candida
The	European	Conference	on	Infections	in	Leukaemia	(ECIL)	5	guide-







and	 in	others	oral	amphotericin	B	 is	given	on	top	of	 fluconazole	 if	

















for	 the	 prevention	 of	 IFD	 in	AML	 patients	 undergoing	 intensive	
chemotherapy.	Its	efficacy	and	cost-	effectiveness	have	been	dem-
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therapy	and	proceed	to	BAL	sampling	when	 infiltrates	are	docu-
mented.	Indeed,	a	survival	benefit	of	azole	prophylaxis	compared	
with	 a	 diagnostic-	driven	 approach	 has	 not	 been	 convincingly	
shown	and	so	both	continue	to	be	reasonable	strategies.
4.3 | Mould- active prophylaxis in GVHD







the	 overall	 mortality	 did	 not	 differ.14	 All	 centres	 administer	 azole	
prophylaxis	 (4	posaconazole,	2	voriconazole,	2	 itraconazole)	to	pa-




Pulmonary	 imaging	with	high-	resolution	CT	 (HRCT)	was	 shown	 to	
accelerate	and	improve	the	diagnosis	of	IA.23	The	IDSA	guideline	ad-
vocates	imaging	with	chest	CT	when	a	patient	is	suspected	to	have	




patients	 and	 the	 specificity	 has	 varied	 between	 studies.23,24 Only 
one	centre	routinely	monitors	serum	GM	in	patients	with	prolonged	









(RAMs)	 in	 the	 cyp51A-	gene	 (TR34/L98H,	 TR53,	 and	 TR46/Y121F/
T289A)	and	is	most	likely	caused	by	the	environmental	use	of	azole	
fungicides.7,26,27	The	TR34/L98H	and	TR46/Y121F/T289A	accounted	




mortality.5,8	 The	 diagnostic	 tools	 used	 for	 the	 detection	 of	 azole-
resistance	 vary	 from	 centre	 to	 centre.	 Most	 perform	 agar-	based	
screening	 assays	 for	 resistance	 (VIPcheck™	 testing).	 Phenotypic	
azole-resistance	 testing	 according	 to	 the	 EUCAST	 method	 is	
performed	 by	 the	 National	 mycology	 reference	 laboratory	 only	
(RefLab).	Four	centres	directly	send	Aspergillus	strains	to	the	RefLab	
and	three	await	the	result	of	the	screening	assay.
Only	 very	 recently,	 the	 clinical	 validity	 and	 relevance	 of	 PCR-	
based	 susceptibility	 testing	 on	 BAL	 was	 demonstrated	 and	 may	
explain	 the	 limited	 uptake	 of	 resistance	 detection	 by	 PCR	 at	 the	
time	 of	 the	 survey.	 The	 AsperGenius®	 qPCR	 is	 a	 multiplex	 PCR	
and	 can	 detect	 the	 presence	 of	 Aspergillus	 DNA	 and	 in	 addition	













ture.6	 These	data	 are	based	on	 clinical	 isolates	 and	 it	 is	 uncertain	
what	fraction	of	these	patients	met	EORTC/MSG	criteria.	However,	
the	 clinical	 relevance	 of	 azole-resistance	 in	 patients	with	 an	 inva-
sive	Aspergillus	infection	was	described	in	a	recent	multicenter	study	
and	small	case	series	have	reported	a	very	high	mortality	in	patients	
infected	 with	 a	 voriconazole	 resistant	 A. fumigatus	 that	 received	






cally	 stable	 while	 awaiting	 culture	 and/or	 resistance	 PCR	 results.	
In	a	clinically	unstable	patient,	 five	centres	still	 start	voriconazole,	






































Following	 this	 survey,	 a	 consensus	 meeting	 was	 organised	 with	
representatives	 of	 all	 8	 centres	 and	 led	 to	 the	 development	 of	 a	
	standardised	diagnostic	and	therapeutic	protocol	on	the	management	
of	 IFD	 in	haematology	patients	 (Figure	1).	This	protocol	was	devel-
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optimal	approach	towards	IFD	in	the	context	of	azole-resistance	(The	












Treatment	with	 L-	AmB	 is	 advised	when	 azole-	resistance	 is	 doc-





vivo	 in	 immunocompetent	 and	 immunosuppressive	 murine	 models	








The	 logical	 behind	 the	 posaconazole	 strategy	 is	 the	 observation	
that	Aspergillus	 strains	 carrying	 RAMs	 often	 have	 a	 posaconazole	
minimum	 inhibitory	 concentrations	 (MIC)	 that	 is	 <2	mg/L.36	 The	
efficacy	 of	 posaconazole	 at	 high	 serum	 levels	 was	 demonstrated	




as	 serum	 drug	 levels	 are	 sufficiently	 high.	No	 human	 data	 on	 the	
use	of	this	treatment	strategy	have	been	published.	However,	 in	a	
phase	3	pharmacokinetics	and	safety	study	for	posaconazole	tablets	
the	 average	 serum	 concentration	of	 posaconazole	 in	 quartile	 4	 of	
the	186	patients	that	received	posaconazole	tablets	at	300	mg	per	
day	was	2.3-	9.5	mg/L.	 It	was	not	associated	with	a	 specific	 safety	
signal	and	therefore,	a	serum	level	between	3	and	4	mg/L	is	a	realis-
tic	target.38	Posaconazole	with	high	serum	trough	levels	is	the	only	
oral	 step-	down	 treatment	 option	 for	 patients	with	 azole-	resistant	
IA.	Although	clinical	evidence	remains	anecdotal,	preclinical	animal	
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